Slingshot members are tracking this event:

Pfizer Announces Positive Top-Line Results From Second Phase 3 Trial Of Oral XELJANZ (Tofacitinib Citrate) In Adults With Psoriatic Arthritis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
PFE Community voting in process

Additional Information

Additional Relevant Details This study evaluated the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adult patients with active PsA who had an inadequate response to at least one tumor necrosis factor inhibitor (TNFi), making it the first PsA study to focus exclusively on TNFi-IR patients.1 OPAL Beyond met its primary efficacy endpoints demonstrating a statistically significant (p<0.0001) improvement with tofacitinib 5 mg BID and 10 mg BID compared to placebo treatment as measured by American College of Rheumatology 20 (ACR20) response and Health Assessment Questionnaire Disability Index (HAQ-DI) score at 3 months.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Oral Xeljanz, Tofacitinib Citrate, Psoriatic Arthritis